Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR

Valiant Organics to start production of OAP and Pharma Intermediates

Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23

Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%

Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore

Tosoh to increase production capacity of separation and purification media

Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

PIB: Quality control of Ayush drugs

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.

PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.

India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.

USFDA issues 3 observations for Aurobindo Pharma’s Unit XI

The company has responded to the warning letter and carried out the committed corrections.